Mobile website
Archive > Volume 29 Issue 8 > 2022,29(8):708-713. DOI:10.3872/j.issn.1007-385X.2022.08.002 Prev Next
Expert Forum
Gastrointestinal stromal tumor: immune microenvironment characteristics and immunotherapy ideas
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor in the gastrointestinal tract, which is insensitive to radiotherapy or chemotherapy. In the past two decades, the tyrosine kinase inhibitors (e. g. imatinib) have greatly improved the prognosis of patients with GIST, but primary or secondary drug resistance occurred in a considerable number of patients. Therefore, it is necessary to explore new treatments. With the development of basic and clinical researches in tumor immunotherapies, more and more patients with various tumors have benefited from immunotherapy. However, the application of immunotherapy in the treatment of GIST progressed rather slowly. Although there is some progress in immune checkpoint therapy for GIST, more evidence is required in the future. In the promising fields of immune cell therapy and neoantigen vaccine, no new technology has been introduced into the clinical studies of GIST. Nevertheless, GIST has abundant immune cell infiltration in immune microenvironment, suggesting that GIST may benefit from immunotherapy. Instead of directly using the characteristics of epithelium-derived tumors, immunotherapy studies in GIST should be based on thorough understanding of the unique immune signature of GIST. Only through targeted researches and GIST-specific immunotherapy, could immunotherapy of GIST truly improve the prognosis of patients with GIST.
Keywords:
Project Supported:
Clc Number:
